Agents in late-stage development for the treatment of rare cancers.
ARS Pharmaceuticals Submits sNDA for Neffy to Treat Anaphylaxis in Small Children
If approved, neffy would be the first new delivery method in more than 35 years for small children.
Read More
Study Finds Cap on Out-of-Pocket Costs Saves Cancer Patients $7,000
The Inflation Reduction Act’s limit on Medicare Part D spending can lead to savings for patients prescribed oral chemotherapy drugs.
KFF: Large Numbers of People Clinically Eligible for GLP-1 Drugs
This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on currently approved FDA indications, including 36.2 million people with obesity.
Evernorth Will Offer a Private-Label Stelara Biosimilar in 2025
The private-label biosimilar will be available at an 80% discount off Stelara. Evernorth has not released information about which company will be producing the biosimilar.
Can Outcomes-Based Agreements Work for Weight Loss Drugs?
Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something that’s not going to work.
Analysis: Consumer Out-of-Pocket Drug Costs Rise Faster than Insurer Costs
The growth of out-of-pocket and insurer/negotiated prices paralleled one another until 2016 when negotiated and insurer prices began declining
